Viral and Non-Viral Vector Manufacturing Market Vendor and Technology Assessment Report 2024-2031

Viral and Non-Viral Vector Manufacturing Market worth $23.49 billion by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Viral and Non-Viral Vector Manufacturing Market (Vector Type (Viral Vector (Adenoviral Vector, Retroviral Vector, Adeno-Associated Viral Vector, Lentiviral Vector, Vaccinia Viral Vector, Other Viral Vector), Non-Viral Vectors, (Plasmid DNA, Lipid-Based Non-Viral Vector, Polymer-Based Non-Viral Vector, Other Non-Viral Vector (Peptide-Based And Hybrid/Combination))), Diseases (Cancer, Genetic Disorder, And Infectious Diseases), Application (Gene Therapy (Viral Vector, Non-Viral Vector), Vaccinology (Viral Vector, Non-Viral Vector), Cell Therapy (Viral Vector, Non-Viral Vector) And Other Applications (Viral Vector, Non-Viral Vector))) - Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get Free Access to Demo Report, Excel Pivot and ToC : https://www.insightaceanalytic.com/request-sample/1263

The market for the production of viral and non-viral vectors is estimated to be worth US$ 5.01 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 19.04% from 2022 to 2030 to reach US$ 23.49 billion.
The use of vectors in advanced gene and cell therapies has had a major impact on medicine. Genetically modified therapies have shown great promise in the treatment of a number of neurological conditions and chronic illnesses. Numerous illnesses could be effectively treated and managed with gene therapy. Viral vectors are the most often used agents in gene therapy because of their remarkable ability to deliver therapeutic gene copies to host cells. Among this class of vectors, adeno-associated vectors (AAV) are the most promising because of their short half-life, capacity to transduce both dividing and non-dividing cells, and minimal immunogenicity. The main drivers of the market's growth include a number of factors, such as the growing incidence of deadly illnesses and the growing use of next-generation technologies in the creation of novel medications.The Development of different viral and non-viral vectors to solve unmet medical needs has been further highlighted by the encouraging outcomes of vector-based therapeutics in a number of clinical studies.
main drivers of the market's growth include a number of factors, such as the growing incidence of deadly illnesses and the growing use of next-generation technologies in the creationnovel medications. The market is expected to grow significantly in the coming years due to a number of factors, including the growing use of vector-based gene and cell therapies, the high demand for customized drugs, the rising R&D expenditures forvector-based therapeutic innovations, and the established healthcare infrastructures. The need for treatments involving genetic modification is rising due to the prevalence of infectious and chronic diseases, which creates multiple opportunities for the market for the production of viral and non-viral vectors.
On the other hand, low transfection efficiency, the difficulties of producing viral and non-viral vectors on a large scale, and the high cost of vector manufacture could impede market growth in the next years.
Due to the rapid adoption of sophisticated therapeutic techniques and the growing R&D efforts in vector-based therapy innovations, North America is expected to lead the global market for the manufacturing of viral and non-viral vectors in the upcoming years (2020-2030).

Expert Knowledge, Just a Click Away:https://calendly.com/insightaceanalytic/30min?month=2024-02

Key market players operating in the viral and non-viral vector manufacturing market include Boehringer Ingelheim (Germany), Catalent, Inc. (US), FUJIFILM Holdings Corporation(Japan), Danaher Corporation (US), Genscript Biotech Corporation (US), Lonza Group AG (Switzerland), Merck KGaA Inc. (Germany), Oxford Biomedica plc (UK), Sartorius AG (Germany), Takara Bio Inc. (Japan), Thermo Fisher Scientific Inc. (US), Wuxi AppTec (China), Acuitas Therapeutics (Canada), Evonik Industries AG (Germany), Exelead, Inc. (US), Entos Pharmaceuticals (Canada), Genevant Sciences GmbH (Switzerland), T&T Scientific Corporation (US), Moderna, Inc. (US), CureVac N.V. (Germany), Cognate BioServices Inc. (Cobra Biologics), Genezen Laboratories, Yposkesi, Waisman Biomanufacturing, Advanced Bioscience Laboratories, Inc. (Abl Inc.), Novasep Holding S.A.S., Batavia Biosciences B.V., Biovion Oy, Sirion Biotech Gmbh., Virovek Incorporation, Biontech Imfs Gmbh, Vivebiotech S.L., Creative Biogene, Uniqure NV, Cell and Gene Therapy Catapult, Cevec. Pharmaceuticals Gmbh among others.

Key developments in the market:
• In May 2022, Catalent launched its latest UpTempo VirtuosoTM platform method for developing and CGMP production of adeno-associated viral (AAV) vectors. The UpTempo Virtuoso platform standardizes and streamlines several time-consuming procedures in AAV manufacture to drastically minimize the time from gene to clinic and enable quick clinical assessment of the first patient.
• In December 2021, GenScript ProBio (US) opened China's most prominent commercial GMP plasmid manufacturing facility. The 6,400-square-meter manufacturing plant enables the company to offer global customers a one-stop service for plasmids - from the preclinical study (IIT) to the investigational new drug (IND) filing to clinical trial and commercial manufacturing - to accelerate the innovation and development of high-quality cell and gene therapy mRNA drugs.
• In December 2021, Oxford Biomedica plc (UK) extended a commercial supply agreement with Novartis to manufacture lentiviral vectors for several Novartis CAR-T products.
• In October 2021, Matica Biotechnology, Inc, a (CDMO) specializing in the clinical and commercial production of cell and gene therapies, announced a joint research agreement (JRA) with Sartorius, a leading international partner of the biopharmaceutical industry. Under this agreement, Matica Bio and Sartorius will work on several studies to streamline and optimize PAT technologies, automation software, and single-use platforms offered by Sartorius for large-scale vector production.
• In April 2021, Oxford Biomedica plc (UK) signed a new three-year Development & Supply Agreement ("DSA") with Boehringer Ingelheim to manufacture & supply various types of the viral vector.
• In Jan 2021, Thermo Fisher Scientific Inc. and Groupe Novasep SAS (Novasep) announced that Thermo Fisher acquired Novasep's viral vector manufacturing company in Belgium, Henogen S.A. The viral vector manufacturing division of Novasep offers contract manufacturing services for vaccines and medicines to biotechnology and major biopharma clients.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1263

Market Segments

Viral and Non-Viral Vector Manufacturing Market, by Vector Type, 2020-2030 (Value US$ Mn)
• Viral Vector
o Adenoviral Vector
o Retroviral Vector
o Adeno-Associated Viral Vector
o Lentiviral Vector
o Vaccinia Viral Vector
o Other Viral Vector
• Non-Viral Vectors
o Plasmid DNA
o Lipid-Based Non-Viral Vector
o Polymer-Based Non-Viral Vector
o Other Non-Viral Vector (Peptide-Based and Hybrid/Combination)

Viral and Non-Viral Vector Manufacturing Market, by Disease, 2020-2030 (Value US$ Mn)
• Cancer
• Genetic Disease
• Infectious Disease
• Cardiovascular Disease
• Other Diseases

Viral and Non-Viral Vector Manufacturing Market, by Application, 2020-2030 (Value US$ Mn)
• Gene Therapy
o Viral Vector
o Non-Viral Vector
• Vaccinology
o Viral Vector
o Non-Viral Vector
• Cell Therapy
o Viral Vector
o Non-Viral Vector
• Other Applications
o Viral Vector
o Non-Viral Vector

Viral and Non-Viral Vector Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Viral and Non-Viral Vector Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global viral and non-viral vector manufacturing market
 To receive an industry overview and future trends of the viral and non-viral vector manufacturing market
 To analyze the viral and non-viral vector manufacturing market drivers and challenges
 To get information on the viral and non-viral vector manufacturing market size (Value US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the viral and non-viral vector

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1263

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.